CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 915 enrolled
Drug / intervention
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody +2 moredrug
Likely dose
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody 1200 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02420821
NCT02420821Phase 3Completed
CompareCT.gov

A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

Hoffmann-La Roche·interventional·Posted Apr 20, 2015·Updated Jan 30, 2023

In Brief

A Phase 3 clinical trial evaluating Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, and 1 other intervention for Renal Cell Carcinoma. Completed, enrolled 915 participants across 154 sites in 21 countries.

Detailed Summary

This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesAustralia, Bosnia and Herzegovina, Brazil, Canada, Czechia, Denmark, France, Germany, Italy, Japan, Mexico, Poland, Russia, Singapore, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 20, 2015
Enrollment StartMay 20, 2015
Primary CompletionFeb 14, 2020
Study CompletionDec 13, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 11.2 years ago

Interventions

Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibodydrug

Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle.

Bevacizumabdrug

Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle.

Sunitinibdrug

Sunitinib will be administered at a dose of 50 mg once daily, orally via capsule, on Day 1 through Day 28 of each 42-day cycle.